Quantum Biopharma EBITDA 2019-2024 | QNTM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Quantum Biopharma ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Quantum Biopharma ebitda from 2019 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$180.1B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$126.3B
Gilead Sciences (GILD)	$103.5B
Bristol Myers Squibb (BMY)	$101.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$90.3B
Alnylam Pharmaceuticals (ALNY)	$34.7B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.4B
Biogen (BIIB)	$29.1B
Moderna (MRNA)	$26.6B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.1B
Genmab (GMAB)	$17.6B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.8B
Vaxcyte (PCVX)	$12.8B
Insmed (INSM)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.1B
Halozyme Therapeutics (HALO)	$8B
Intra-Cellular Therapies (ITCI)	$8B
Repligen (RGEN)	$7.8B